IVIG use during pregnancy was associated with a significantly higher LBR among RPL women, particularly when initiated between 6-12 weeks of gestation and administered at a dose <20 g/d; these associations remained robust after excluding cases with abnormal karyotypes. These findings suggest that IVIG may be an effective immunological intervention for improving pregnancy outcomes in selected RPL patients.
Xin et al. (Wed,) studied this question.